HEP DART 2005 -- frontiers in drug development for viral hepatitis.
Feitelson
Mark A
MA
Thomas Jefferson University, Department of Pathology, Anatomy and Cell Biology, Room 222 Alumni Hall, 1020 Locust Street, Philadelphia, PA 19107, USA. Mark.Feitelson@jefferson.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000209:etiology / Q000628:therapy*
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D017325:Hepatitis B Vaccines